Biotech Stock

World Stem Cell Summit

October 5, 2011

World Stem Cell Summit concludes on 5th October 2011 in Pasanda. Hundreds of experts in the field will be discussing stem cell breakthroughs and roadblocks. Among the cutting-edge discoveries for discussion are “induced pluri potent cells”. Clive Svendsen at the Cedars-Sinai Regenerative Medicine Institute says those cells let scientists do “disease in a dish” research. [...]

Read the full article →

Zaltrap Helps REGN to Pop

April 27, 2011

Shares of biopharma company Regeneron Pharmaceuticals spiked today, rising as much as 38% on huge volume closing at $67.00. REGN and partner SNY announced positive results from its phase III study of Zaltrap, a treatment for metastatic colorectal cancer. When used in combination with chemotherapy, Zaltrap was able to improve overall survival for patients versus [...]

Read the full article →

Vivus’s Diet Pill Scores

April 4, 2011

Vivus’s experimental diet pill Qnexa helps lower blood pressure and cholesterol. Once-daily Qnexa helped reduce dependence on blood-pressure pills by as much as 19 percent on average and decrease triglycerides by 26 percent, according to research presented yesterday at the American College of Cardiology meeting in New Orleans. No new safety risks were found among [...]

Read the full article →

MultiStem Shows Hope in Spinal Cord Injury

January 22, 2011

There is another good reason for Investing in Athersys(NASDAQ:ATHX). A new research shows Athersys’  stem cell technology could possess therapeutic benefits in treating spinal cord injuries. Researchers discovered that administering Athersys’ MultiStem technology to rodents with spinal injuries reduced inflammation and promoted the regrowth of neurons, according to a testimony from Athersys and the Case Western Reserve [...]

Read the full article →

Advanced Cell Technology Receives FDA Clearance For Clinical Trial to Treat SMD

November 22, 2010

MARLBOROUGH, Mass.– Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC) announced today that the US Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (HESCs) to treat patients with Stargardt’s Macular Dystrophy (SMD), one [...]

Read the full article →

← Previous Entries